Policy Cures Research is a global health think tank with a long and pioneering history in global health R&D data collection and analysis, securing our position as a trusted source of quality evidence within the sector.

Originally the research and policy division within Policy Cures, Policy Cures Research separated from Policy Cures in 2016 to focus on the generation of evidence within the global health R&D sector. Policy Cures itself was previously hosted by the London School of Economics (LSE) and the George Institute for International Health, before becoming an independent group in June 2010.

Our specialist experience in the field of global health R&D has enabled us to build extensive networks through which we partner and collaborate. These relationships encompass key funders of global health R&D, such as the Bill & Melinda Gates Foundation, US NIH, Wellcome Trust, UK DFID, and USAID, as well as Product Development Partnerships, the pharmaceutical industry, and academic research institutions.

Our analysis is independent, accurate and impartial

Policy Cures Research stakes its reputation on providing robust and unbiased analysis built on an in-depth understanding of, and relationships with, organisations from across the R&D spectrum, including governments, multilaterals, the private and philanthropic sectors, and civil society.

We hold no affiliations and accept no funding that might bias our research, and remain committed to providing rigorous, impartial and actionable analysis to advance the progress of global health R&D to help those most in need.

Work with us

We are a diverse and dynamic team, drawing together a range of academic and professional backgrounds. We work every day to gather and communicate evidence to drive research and innovation for historically neglected and underfunded health issues. If you think you could contribute to our work and wish to discuss employment opportunities, please feel free to get in touch.

Current vacancies

Senior Analyst, Neglected Diseases– Europe or Australia-based

Our team

Our team’s expertise and experience is focused on product development and global health; from R&D activities and portfolios, to developers, business models, and funding approaches – including incentives, pricing and access.

We are able to draw on a wide range of public and private sector experience in global health, R&D, medicine, economics, international health policy, and international and intellectual property law. Between us, we hold three medical degrees, three PhDs, 10 Masters degrees, speak 5 languages, and have over 75 years of experience in global health.

Our cross-disciplinary team combines a diverse range of specialist knowledge, allowing us to develop fresh, innovative solutions to address the questions and challenges facing the global health R&D sector. In this way, we are able to nimbly move beyond traditional approaches and adapt ideas, in real time, to today’s changing world.

Richard Fisher

Executive Chairman

Dr Nick Chapman

Chief Executive Officer

Anna Doubell

Chief Operating Officer

Andrew Tuttle

Director of Research

Lisette Oversteegen

Senior Analyst

Dr Paul Barnsley

Senior Analyst

Maya Goldstein

Senior Analyst

Dr Vipul Chowdhary

Technical Lead

Juliette Borri


Dr Amelia Hynen


Madeleine Kearney

Junior Analyst

Thomas Clifton

Junior Analyst

Lee Sternberg

Accounting Manager

Emmanuelle Bomo

Communications Lead

Delfina Rampone

Research assistant

Dr Megan Truong

Research Assistant

Phoebe Nguyen

Research Assistant

Dr Alex Ankomah

Research Assistant

Shavon David

Research Assistant

Our board

Richard Fisher

Executive Chairman

Dr Nick Chapman

Chief Executive Officer

Ronan Lehane

Non-Executive Director

Advisory Committee

Policy Cures Research relies on the expert advice of our Advisory Committee, which is made up of a broad cross-section of international experts in global health and product development, providing us with invaluable advice on the design and scope of our research survey.

  • Dr Ian Askew, Director, Reproductive Health and Research, World Health Organization, Special Programme of Research, Development and Research Training in Human Reproduction (WHO HRP)
  • Dr Ripley Ballou, Vice President and Head, Global Vaccines US R&D Center, Biologicals
  • Professor Balram Bhargava, Director General of the Indian Council of Medical Research
  • Dr Graeme Bilbe, Senior Advisor at Drugs for Neglected Diseases Initiative (DNDi)
  • Dr François Bompart, Director of HIV and Hepatitis C Initiative at Drugs for Neglected Diseases Initiative (DNDi)
  • Martha Brady, Director, Sexual and Reproductive Health, Program for Appropriate Technology in Health (PATH)
  • Dr Yan Che, Professor, Shanghai Institute of Planned Parenthood Research (SIPPR)
  • Dr Jianxing Chen, Professor of Medicinal Chemistry, Director of Drug Research, Shanghai Institute of Planned Parenthood Research (SIPPR)
  • Lester Chinery, Caucus Chair (and Director of Operations, Concept Foundation), Reproductive Health Supplies Coalition (RHSC) – Generic Manufacturers Caucus (GEMS)
  • Dr Wanderley de Souza, Former President of the Financiadora de Estudio e Projetos (FINEP)
  • Dr Laneta Dorflinger, Director, Contraceptive Technology Innovation, FHI 360
  • Dr Emily Erbelding, Director, Division of Microbiology and Infectious Diseases at the National Institute of Allergy and Infectious Diseases, National Institutes of Health
  • Dr Linglig Feng, Associate Professor of Pharmaceutics, Shanghai Institute of Planned Parenthood Research (SIPPR)
  • Professor Alan Fenwick, Professor of Tropical Parasitology at Imperial College London
  • Dr Arnuad Fontanet, Head of Emerging Diseases Epidemiology Unit at Institut Pasteur
  • Jeffrey Jacobs, Director, Product Innovation and Market Access, Merck for Mothers
  • Miles Kemplay, Executive Director, Adolescence, Children’s Investment Fund Foundation (CIFF)
  • Dr Sue Kinn, Team Leader and Research Manager at the UK Department for International Development (DFID)
  • Dr Jean Lang, Associate Vice President at Sanofi Pasteur
  • Dr Smita Mahale, Director, National Institute for Research in Reproductive Health, Indian Council of Medical Research (ICMR)
  • Dr Timothy Mastro, Chief Science Officer, FHI 360
  • Dr Carl Mendel, Senior Vice President, Research & Development at TB Alliance
  • Hanke Nubé, Senior Health Advisor, The Dutch Directorate-General for International Cooperation (DGIS), Ministry of Foreign Affairs
  • Professor Oladapo A. Ladipo, President, CEO, Association of Reproductive and Family Health (ARFH), Nigeria
  • Dr Firdausi Qadri, Senior Scientist and Head of Immunology at the International Centre for Diarrhoeal Disease and Research (icddr,b)
  • Kate Rademacher, Technical Advisor, FHI 360
  • Dr Saumya RamaRao, Caucus Chair (and Senior Program Associate, Population Council), Reproductive Health Supplies Coalition (RHSC) – Caucus for New and Underused RH Technologies
  • Dr John Reeder, Director at the World Health Organization; Special Programme for Research and Training in Tropical Disease (WHO/TDR)
  • Professor Helen Rees, Founder, Executive Director, University of Witwatersrand – Reproductive Health and HIV Institute (WITS RHI)
  • Dr Malabika Roy, Independent expert (ex-Indian Council of Medical Research (ICMR))
  • Professor Nelson Sewankambo, Professor of Internal Medicine at Makerere University College of Health Sciences
  • Dr Joseph Speidel, Professor, Department of Obstetrics, Gynecology & Reproductive Sciences, Director Emeritus and Senior Scholar, Bixby Center for Global Reproductive Health, University of California, San Francisco (UCSF)
  • Kathryn Stewart, Deputy Director, CAMI-Health / Initiative for MPTs (IMPT)
  • Dr Soumya Swaminathan, former Deputy Director-General for Programmes at the World Health Organization
  • Dr Melanie Taylor, Medical Officer, Sexually Transmitted Infections Programme, World Health Organization, Special Programme of Research, Development and Research Training in Human Reproduction (WHO HRP)
  • Wendy Taylor, Fellow at The Rockefeller Foundation
  • Dr Marleen Temmerman, Professor, Department of Obstetrics and Gynaecology, Director Women’s Health, Faculty of Health Sciences, Aga Khan University, Nairobi
  • Dr John Townsend, Director, Country Strategy, Population Council
  • Dr Tim Wells, Chief Scientific Officer at Medicines for Malaria Venture (MMV)
  • Dr Bethany Young Holt, Executive Director, CAMI-Health / Initiative for MPTs (IMPT)